Registry following patients with several cancers treated by MR-Linac radiation therapy
Records outcomes of cancer patients receiving radiation therapy with the Unity MR-Linac machine.
Key facts
- Who runs it
- UMC Utrecht
- Where
- Houston, Milwaukee, and Pittsburgh, United StatesSee the 3 sitesAlso in 8 other countries, 15 sites
- Trial code
- Registry title
- The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
- Status
- Recruiting
- People taking part
- 8,000 people, planned
- Started
- 1 Feb 2019
- Expected to end
- 1 Aug 2030
- Type of study
- Observational, 13 groups
- Treatments tested
- Radiation therapy
- Record updated
- 5 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who will have, or have had, imaging or radiation treatment on an MR-Linac machine, for example for breast, prostate, gynecologic or brain tumors.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Earlier treatment
- Patients who are going to have, or have completed, imaging or treatment on an MR-Linac.
Main reasons for not taking part
- MRI contraindications as in usual clinical care
- Possible pregnancy
- Claustrophobia
- Metal or electronic implants not compatible with MRI
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac
- Patient provides written, informed consent
- Patient is 18 years old or older
Who cannot take part
- MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI
- MRI exclusion criteria, including
Where in United States
Also in 8 other countries, 15 sites
- MD Anderson Cancer CenterHouston, United StatesContact: Clifton D FullerTaking people
- Medical College of WisconsinMilwaukee, United StatesContact: William A HallTaking people
- Allegheny Health NetworkPittsburgh, United StatesContact: Tom ColoniasTaking people
About the trial
What the trial wants to find out
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.
The 13 groups in the trial
- Brain cancer
Treatment: Radiation therapy
- Lung cancer
Treatment: Radiation therapy
- Esophageal cancer
Treatment: Radiation therapy
- Breast Cancer
Treatment: Radiation therapy
- Head and Neck Cancer
Treatment: Radiation therapy
- Pancreatic cancer
Treatment: Radiation therapy
- Gynecological cancer
Treatment: Radiation therapy
- Rectal cancer
Treatment: Radiation therapy
- Prostate cancer
Treatment: Radiation therapy
- Bladder cancer
Treatment: Radiation therapy
- Oligometastases
Treatment: Radiation therapy
- Liver cancer
Treatment: Radiation therapy
- Other types of cancer
Treatment: Radiation therapy
Results explained
A paper that names this trial, explained in plain words.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
- Plain-language title
- Registry following patients with several cancers treated by MR-Linac radiation therapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Acute adverse events in the DESTINATION 1 trial: A prospective prostate SBRT dose de-escalation feasibility study.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2026
- Record updated
- 5 March 2026